natgillin/translations-raw huggingface dataset:
In the intention to treat analysis, 939 events were observed in the clopidogrel group and 1,020 events with ASA (relative risk reduction (RRR) 8.7%, [95% CI: 0.2 to 16.4]; p=0.045), which corresponds, for every 1,000 patients treated for 2 years, to 10 [CI: 0 to 20] additional patients being prevented from experiencing a new ischaemic event.
Pri analizi vključenih bolnikov (intention to treat analysis) so v skupini, ki je jemala klopidogrel, opazili 939 dogodkov, v skupini, ki je jemala ASA, pa 1.020 dogodkov (zmanjšanje relativnega tveganja /RT/: 8,7%%, 95-odstotni interval zaupanja /IZ/: 0,2 do 16,4; p = 0,045), kar ustreza preprečevanju pojava novega ishemičnega dogodka na vsakih 1.000 bolnikov, zdravljenih 2 leti, dodatnim 10 (IZ: 0 do 20) bolnikom.
In the intention to treat analysis, 939 events were observed in the clopidogrel group and 1,020 events with ASA (relative risk reduction (RRR) 8.7%, [95% CI: 0.2 to 16.4]; p=0.045), which corresponds, for every 1,000 patients treated for 2 years, to 10 [CI: 0 to 20] additional patients being prevented from experiencing a new ischaemic event.
Pri analizi vključenih bolnikov so v skupini, ki je prejemala klopidogrel, opazili 939 dogodkov in v skupini, ki je prejemala ASA, 1.020 dogodkov (zmanjšanje relativnega tveganja (RT) 8,7 %, [95 % IZ: 0,2 do 16,4]; p=0,045), kar ustreza preprečevanju pojava novega ishemičnega dogodka na vsakih 1.000 bolnikov, zdravljenih 2 leti, dodatnim 10 [IZ: 0 do 20] bolnikom.
In the international multicentre, double-blind SAILING study (ING111762), 719 HIV-1 infected, antiretroviral therapy (ART)-experienced adults were randomized and received either dolutegravir 50 mg once daily or raltegravir 400 mg twice daily with investigator selected background regimen consisting of up to 2 agents (including at least one fully active agent).
V mednarodni, multicentrični, dvojno slepi študiji SAILING (ING111762) je bilo 719 odraslih, okuženih z virusom HIV, ki so že prejemali protiretrovirusno terapijo (ART), randomiziranih v skupino, ki je prejemala 50 mg dolutegravirja enkrat na dan, ali v skupino, ki je prejemala 400 mg raltegravirja dvakrat na dan, raziskovalec pa je izbral osnovno shemo, sestavljeno iz do največ 2 učinkovin (vključno z vsaj eno polno aktivno učinkovino).
In the intravenous bolus studies, the doses that were well- tolerated decreased with increasing study duration: 0.2 and 0.02 mg/kg daily was well tolerated for 4 weeks in rats and dogs, respectively but only 0.01 mg/kg and 0.005 mg/kg in rats and dogs, respectively, when given for 52 weeks.
V študijah z intravenskimi bolusi so se odmerki, ki so jih živali dobro prenašale, zmanjševali s podaljševanjem študije: odmerek 0,2 oziroma 0,02 mg/kg na dan so podgane in psi dobro prenašali 4 tedne, medtem ko so tako podgane kot psi 52 tednov dolgo dajanje zdravila dobro prenašali le v odmerku 0,01 mg/kg oziroma 0,005 mg/kg.
In the invasive disease study, Synflorix was shown to be effective in protecting against invasive disease: no cases were seen among the 10,000 children given three doses of Synflorix and a booster, one case was among the 10,000 children given two doses of Synflorix and a booster and 12 cases were seen in 10,000 children given the comparator vaccine.
V študiji preprečevanja invazivne bolezni se je cepivo Synflorix izkazalo kot učinkovito pri zaščiti pred invazivno boleznijo: med 10 000 otroki, ki so prejeli tri odmerke cepiva Synflorix in obnovitveni odmerek, se invazivna bolezen ni pojavila; pojavila se je pri enem od 10 000 otrok, ki so prejeli dva odmerka cepiva Synflorix in obnovitveni odmerek, ter pri 12 od 10 000 otrok, ki so prejeli primerjalno cepivo.
In the investigator sponsored CHIPS study (Chronic Hepatitis C International Paediatric Study), 65 children and adolescents (6-18 years) with chronic HCV infection were treated with Pegasys
V raziskovalčevi študiji CHIPS (Chronic Hepatitis C International Pediatric Study) so 65 otrok in mladostnikov (starih 6 do 18 let) s kronično okužbo s HCV zdravili z zdravilom Pegasys
In the IPASS trial, IRESSA demonstrated superior PFS, ORR, QoL and symptom relief with no significant difference in overall survival compared to carboplatin/paclitaxel in previously untreated patients, with locally advanced or metastatic NSCLC, whose tumours harboured activating mutations of the EGFR tyrosine kinase.
V preskušanju IPASS je zdravilo IRESSA dokazalo, da je boljše glede preživetja brez napredovanja bolezni (PFS), objektivnega deleža odziva (ORR), kakovosti življenja in olajšanja simptomov, brez pomembnih razlik v skupnem preživetju v primerjavi z zdravljenjem s karboplatinom/paklitakselom pri predhodno nezdravljenih bolnikih z lokalno napredovalim ali metastatskim nedrobnoceličnim rakom pljuč, ki imajo tumorje z aktivacijskimi mutacijami tirozin-kinaze EGFR .
In the iPrEx clinical study, no HIV-1 variants expressing K65R, K70E, M184V, or M184I were detected at the time of seroconversion among subjects who became infected with HIV-1 after enrollment in the study.
V klinični študiji iPrEx ni bila zaznana nobena različica HIV–1z izraženo K65R, K70E, M184V ali M184I v času serokonverzije pri osebah, ki so se okužile s HIV–1 po vključitvi v študijo.
In the ITT population of an open label dose response study, DPM-CF-202, the mean (SD) percent change in FEV1 for the 400 mg dose was 8.75 (SD: 12.4) and -1.569 (SD: 9.0) for 40 mg dose (p < 0.0001).
V populaciji z namenom zdravljenja (ITT) nerandomizirane študije odvisnosti učinka in odmerka, DPM-CF-202, je bilo povprečje (standardni odklon, SD) odstotkovne spremembe vrednosti FEV1 za odmerek 400 mg 8,75 (SD: 12,4) in -1,569 (SD: 9,0) za odmerek 40 mg (p <0,0001).
In the ivabradine group, 67% of patients were treated with 7.5 mg twice a day.
V skupini, ki je jemala ivabradin, je 67 % bolnikov prejemalo 7,5 mg dvakrat na dan.
In the Kaiser Permanente trial, efficacy was 87.5 % (95 % CI: 7, 99) against bacteraemic pneumonia due to vaccine serotypes of S. pneumoniae.
V študiji Kaiser Permanente je bila učinkovitost cepiva Prevenar v preprečevanju pnevmokokne pljučnice, ki jo spremlja bakteriemija, proti serotipom bakterije S. pneumoniae, ki so bili vključeni v cepivo, 87,5 % (95-odstotni interval zaupanja: 7, 99).
In the Kaiser Permanente trial, efficacy was 87.5 % (95 % CI: 7, 99) against bacteraemic pneumonia due to vaccine serotypes of S. pneumoniae.
V študiji Kaiser Permanente je bila učinkovitost v preprečevanju pnevmokokne pljučnice, ki jo spremlja bakteriemija, proti serotipom bakterije S. pneumoniae, ki so bili vključeni v cepivo, 87,5 % (95-odstotni interval zaupanja: 7, 99).
In the knee replacement surgery study during the intended treatment period, in the apixaban arm
V študiji pri bolnikih s kirurško zamenjavo kolena so med obdobjem zdravljenja v skupini, ki je prejemala apiksaban, poročali o 4 primerih pljučne embolije.
In the large phase 3 clinical trial, the mean estimated exposure (AUC) of the active metabolite was 19% higher in very elderly patients (≥ 75 years of age) compared to subjects < 75 years of age.
V velikem kliničnem preskušanju faze 3, je bila srednja ocenjena izpostavljenost (AUC) aktivnemu presnovku 19 % višja pri zelo starih bolnikih (≥ 75 let) v primerjavi z osebami < 75 let.
In the large study in patients with coronary heart disease and without clinical heart failure, a specific subgroup of patients who had symptomatic angina had a small but significant increase in the combined risk of cardiovascular death or non-fatal heart attack with Corlentor compared with placebo (3.4% vs 2.9% yearly incidence rates).
V obširni študiji pri bolnikih s koronarno srčno boleznijo in brez kliničnega srčnega popuščanja je bilo v specifični podskupini bolnikov s simptomatsko angino pektoris pri jemanju zdravila Corlentor v primerjavi s placebom opaženo majhno vendar statistično značilno povečanje skupnega tveganja za smrtni izid zaradi kardiovaskularnih zapletov ali za srčni napad brez smrtnega izida (3,4-odstotna v primerjavi z 2,9-odstotno stopnjo letne pogostosti).
In the large study in patients with coronary heart disease and without clinical heart failure, a specific subgroup of patients who had symptomatic angina had a small but significant increase in the combined risk of cardiovascular death or non-fatal heart attack with Procoralan compared with placebo (3.4% vs 2.9% yearly incidence rates).
V obširni študiji pri bolnikih s koronarno srčno boleznijo in brez kliničnega srčnega popuščanja je bilo v specifični podskupini bolnikov s simptomatsko angino pektoris pri jemanju zdravila Procoralan v primerjavi s placebom opaženo majhno vendar statistično značilno povečanje skupnega tveganja za smrtni izid zaradi kardiovaskularnih zapletov ali za srčni napad brez smrtnega izida (3,4-odstotna v primerjavi z 2,9-odstotno stopnjo letne pogostosti).
In the large study that focused mainly on pneumonia, the percentage of children who had bacterial pneumonia was 2.3% (240 out of over 10,000) among those given Synflorix compared with 3% (304 out of over 10,000) among those given the comparator.
V veliki študiji, v kateri so se osredotočili predvsem na pljučnico, je imelo bakterijsko pljučnico 2,3 % (240 od več kot 10 000) otrok, ki so prejeli cepivo Synflorix, v primerjavi s 3 % (304 od več kot 10 000) otrok, ki so prejeli primerjalno cepivo.
In the large subgroup of patients undergoing cancer surgery (69% of the patient population), the VTE rate was 4.7% in the fondaparinux group, versus 7.7% in the dalteparin group.
bili operirani zaradi tumorja (69 % vključenih bolnikov) je bila pojavnost VTE 4,7 % pri bolnikih, ki so prejemali fondaparinuks in 7,7 % pri bolnikih, ki so prejemali dalteparin.
In the larger main study of patients with chronic phase CML, 90% of the patients responded to treatment, with blood levels of platelets and white blood cells returning to within predefined, normal values.
V večji glavni študiji z bolniki s KML v kroničnem obdobju se je na zdravljenje odzvalo 90 % bolnikov, pri čemer so se krvne ravni trombocitov in belih krvnih celic vrnile na vnaprej določene, normalne vrednosti.
In the largest study, 67% of the patients with essential thrombocythaemia (628 out of 934), and 66% of those who could not tolerate or did not respond to other treatments (480 out of 725) had a complete response to Xagrid.
V najobsežnejši študiji je bil pri 67 % (628 od 934) bolnikov z esencialno trombocitemijo in pri 66 % (480 od 725) tistih, ki drugih zdravljenj niso prenašali ali se nanje niso odzvali, odziv na zdravilo Xagrid popoln.
In the largest study, which included 61 haemophilia patients with inhibitors, 84% of the 57 serious bleeds and 59% of the 38 surgical bleeds were controlled effectively with NovoSeven.
V največji študiji, ki je zajela 61 bolnikov s hemofilijo z zaviralci, je bilo zdravilo NovoSeven učinkovito pri 84 % od 57 resnih krvavitev in pri 59 % od 38 krvavitev zaradi kirurškega posega.
In the laser group 67 patients received rescue treatment with Eylea beginning at week 24 (Active Control/ Eylea 2mg group) which resulted in improvement of visual acuity by about 5 letters from week 24 to 52.
V kontrolni skupini z laserskim zdravljenjem je 67 bolnikov v začetku 24. tedna prejelo rešilno zdravljenje z zdravilom Eylea (aktivna kontrola/zdravilo Eylea 2 mg), kar se je kazalo v izboljšanju ostrine vida za 5 črk od 24. do 52. tedna.
In the laser group, where patients were eligible for rescue treatment with Eylea from week 24, the proportion of perfused patients increased to 78% by week 52.
V kontrolni skupini z laserskim zdravljenjem, kjer so bili od 24. tedna bolniki primerni za rešilno zdravljenje z zdravilom Eylea, se je delež perfundiranih bolnikov do 52. tedna povečal dona 78 %.
In the latter study, at the lowest systemic exposure where this anomaly occurred in a single animal, the estimated margin relative to the recommended daily human dose was 2 times more than the recommended daily human dose (800 mg).
V tej zadnji študiji, je bila ob najmanjši sistemski izpostavljenosti (pri kateri se je ta anomalija pojavila pri eni sami živali) ocenjeno, da je bil mejni odmerek glede na priporočeni dnevni odmerek za človeka 2-krat večji od priporočenega dnevnega odmerka za človeka (800 mg).
In the limited data available, there was no evidence of a marked ethnic difference in the PK of olaparib between Japanese and Caucasian patients.
Maloštevilni podatki, ki so na voljo, ne kažejo izrazite etnične razlike v farmakokinetiki olapariba med bolnicami Japonkami in bolnicami belkami.
In the limited number of Black patients weight loss was less pronounced (mean difference to placebo -2.9 kg).
Pri omejenem številu bolnikov črncev je bilo zmanjšanje telesne mase manj izrazito (povprečna razlika v primerjavi s placebom –2,9 kg).
In the limited number of co-infected subjects who did not achieve SVR and for whom population sequencing was performed, the prevalence of post-baseline RAVs was higher than that in mono- infected subjects in study SPRINT-2.
Pri omejenem številu preiskovancev s sočasno okužbo, ki niso dosegli SVR in pri katerih so izvedli populacijsko sekvenciranje, je bila prevalenca RAV po začetku zdravljenja višja kot pri preiskovancih z monoinfekcijo v študiji SPRINT-2.
In the limited number of patients with prior exposure to non-liposomal irinotecan, no benefit of ONIVYDE has been demonstrated.
Pri omejenem številu bolnikov, ki so bili predhodno izpostavljeni neliposomskemu irinotekanu, koristen vpliv zdravila ONIVYDE ni bil ugotovljen.
In the LIR subgroup, the 25 mg dose increased the symptom responder rates in both studies as compared to placebo (Kodiac 4 p=0.001, Kodiac 5 p=0.005).
V podskupini LIR je odmerek 25 mg v primerjavi s placebom povečal delež odziva simptomov v obeh študijah (Kodiac 4 p = 0,001, Kodiac 5 p = 0,005).
In the lomitapide clinical trials, one patient with HoFH developed markedly elevated aminotransferase (ALT 24x ULN, AST 13x ULN) within days of initiating the strong CYP3A4 inhibitor clarithromycin.
V kliničnih preskušanjih lomitapida se je pri enem bolniku s HoFH znatno povišala raven aminotransferaze (ALT 24-kratna vrednost ULN, AST 13-kratna vrednost ULN) v nekaj dneh po uvedbi močnega zaviralca CYP3A4, klaritromicina.
In the long-term exposure population, the overall rate of infections with RoActemra was 108 events per 100 patient years exposure.
V dolgoročno izpostavljeni populaciji je bil celokupni delež okužb med uporabo zdravila RoActemra 108 na 100 bolnik-let izpostavljenosti.
In the long-term exposure population, the overall rate of serious infections (bacterial, viral and fungal) was 4.7 events per 100 patient years.
V dolgoročno izpostavljeni populaciji je bil celokupni delež resnih okužb (bakterijskih, virusnih in glivičnih) 4,7 na 100 bolnik-let.
In the long-term extension study of Protocol 015, 1984 women 16-23 years old during vaccination with Gardasil in the base study were followed.
V dolgotrajnem podaljšanju študije po protokolu 015 so spremljali 1984 žensk, ob cepljenju s cepivom Gardasil v izhodiščni študiji starih od 16 do 23 let.
In the long-term extension study of Protocol 015, 1984 women 16-23 years old during vaccination with Silgard in the base study, were followed.
V dolgotrajnem podaljšanju študije po protokolu 015 so spremljali 1984 žensk, ob cepljenju s cepivom Silgard v izhodiščni študiji starih od 16 do 23 let.
In the long-term extension study of Protocol 019, 684 women 24-45 years old during vaccination with Gardasil in the base study were followed.
V dolgotrajnem podaljšanju študije po protokolu 019 so spremljali 684 žensk, ob cepljenju s cepivom Gardasil v izhodiščni študiji starih od 24 do 45 let.
In the long-term extension study of Protocol 019, 684 women 24-45 years old during vaccination with Silgard in the base study, were followed.
V dolgotrajnem podaljšanju študije po protokolu 019 so spremljali 684 žensk, ob cepljenju s cepivom Silgard v izhodiščni študiji starih od 24 do 45 let.
In the long-term extension study of Protocol 020, 918 men 16-26 years old during vaccination with Gardasil in the base study were followed.
V dolgotrajnem podaljšanju študije po protokolu 020 so spremljali 918 moških, ob cepljenju s cepivom Gardasil v izhodiščni študiji starih od 16 do 26 let.
In the long-term extension study of Protocol 020, 918 men 16-26 years old during vaccination with Silgard in the base study, were followed.
V dolgotrajnem podaljšanju študije po protokolu 020 so spremljali 918 moških, ob cepljenju s cepivom Silgard v izhodiščni študiji starih od 16 do 26 let.
In the long-term extension trial (50 weeks), a total of 34.8 % of subjects experienced clinically significant weight increase (i.e., ≥ 7 % increase in body weight at endpoint).
V dolgotrajnem podaljšanem preskušanju (50 tednov) je imelo skupno 34,8 % preiskovancev klinično pomembno povečanje telesne mase (t.j. ≥ 7 % povečanje telesne mase pri končnem rezultatu).
In the long-term outcome trial, a total of 2072 patients received 30 mg tolvaptan with standard of care (SC) and 2061 received placebo with SC.
V dolgoročnem preskušanju za pridobitev rezultatov je skupaj 2072 bolnikov prejelo 30 mg tolvaptana s standardno oskrbo (SO), 2061 pa jih je s SO prejemalo placebo.
In the long-term randomised withdrawal study, abnormal increases of ≥ 7% in body weight from double-blind baseline to double-blind end point were reported for 10% subjects in the TREVICTA group and 1% subjects in the placebo group.
V dolgotrajnem randomiziranem preskušanju odtegnitve zdravila so od začetka do konca dvojno slepega zdravljenja poročali o nenormalnem zvečanju telesne mase za ≥ 7%, in sicer pri 10% preiskovancev v skupini z zdravilom TREVICTA in pri 1% preiskovancev v skupini s placebom.
In the long-term studies, Abilify was more effective than placebo, and as effective as haloperidol, after up to a year of treatment.
V dolgoročnih študijah je zdravilo Abilify v obdobju do enega leta zdravljenja pokazalo večjo učinkovitost kot placebo in enako učinkovitost kot haloperidol.
In the LTPS, there were 263 evaluable zoster cases reported among 261 patients [10.3/1000 person- years].
Tekom študije LTPS so med 261 bolniki zabeležili 263 primerov herpesa zostra, ki jih je bilo možno ovrednotiti [10,3/1.000 oseb-let].
In the lung cancer study in patients with activating EGFR mutations, patients on Avastin plus erlotinib had progression-free survival of 16.0 months on average compared with 9.7 months in patients given erlotinib alone.
V študiji pljučnega raka pri bolnikih z EGFR aktivirajočimi mutacijami je bil pri bolnikih, ki so jemali Avastin skupaj z erlotinibom, povprečni čas preživetja brez napredovanja bolezni 16,0 meseca v primerjavi z 9,7 meseca pri bolnikih, ki so prejemali zgolj erlotinib.
In the lung/gut neuroendocrine tumour study, patients who took Afinitor lived for an average of 11 months without the disease getting worse, compared with around 4 months for patients given placebo.
V študiji nevroendokrinega tumorja pljučnega ali črevesnega izvora so bolniki, ki so jemali zdravilo Afinitor, v povprečju 11 mesecev živeli brez poslabšanja bolezni v primerjavi s 4 meseci pri bolnikih, ki so jemali placebo.
In the main clinical efficacy studies, lurasidone was administered at doses of 37-148 mg lurasidone (equivalent to 40-160 mg lurasidone hydrochloride).
V glavnih študijah klinične učinkovitosti so lurasidon uporabljali v odmerkih od 37 do 148 mg lurasidona (kar ustreza 40-160 mg lurasidonijevega klorida).
In the main field study, dogs of various breeds, age groups, gender and different weights were treated with either Certifect or a similar ‘spot-on’ medicine containing fipronil and (S)-methoprene.
V glavni terenski študiji so pse različnih pasem, starostnih skupin, spola in različnih telesnih mas zdravili z zdravilom Certifect ali podobnim zdravilom za kožni nanos, ki vsebuje fipronil in (S)-metopren.
In the main study in axial spondyloarthritis, 58% of patients receiving Cimzia 200 mg every 2 weeks and 64% of patients receiving Cimzia 400 mg every 4 weeks achieved at least a 20% reduction compared with 38% of patients receiving placebo.
V glavni študiji aksialnega spondiloartritisa je do najmanj 20-odstotnega zmanjšanja prišlo pri 58 % bolnikov, ki so vsaka dva tedna prejemali 200-miligramski odmerek zdravila Cimzia, in pri 64 % bolnikov, ki so vsake štiri tedne prejemali 400-miligramski odmerek zdravila Cimzia, v primerjavi z 38 % bolnikov, ki so prejemali placebo.
In the main study in PNH, 49% of the adult patients receiving Soliris had stable haemoglobin levels (21 out of 43), and, on average, they did not need any transfusions of red blood cells.
V glavni študiji zdravila pri paroksizmalni nočni hemoglobinuriji je imelo 49 % (21 od 43) odraslih bolnikov, ki so prejemali zdravilo Soliris, stabilne ravni hemoglobina in v povprečju niso potrebovali transfuzij rdečih krvnih celic.
In the main study involving 828 patients with COPD, two different doses of Bretaris Genuair (200 and 400 micrograms) given twice a day were compared with placebo (a dummy treatment).
V glavni študiji, v katero je bilo vključenih 828 bolnikov s KOPB, so dva odmerka zdravila Bretaris Genuair (200 in 400 mg), vzeta dvakrat na dan, primerjali s placebom.
In the main study involving 828 patients with COPD, two different doses of Eklira Genuair (200 and 400 micrograms) given twice a day were compared with placebo (a dummy treatment).
V glavni študiji, v katero je bilo vključenih 828 bolnikov s KOPB, so dva odmerka zdravila Eklira Genuair (200 in 400 mg), vzeta dvakrat na dan, primerjali s placebom.
In the main study Pravafenix was shown to be more effective than pravastatin alone in reducing non- HDL-cholesterol levels.
V glavni študiji se je zdravilo Pravafenix izkazalo kot učinkovitejšega od samega pravastatina pri zniževanju ravni holesterola zaradi lipoproteinov nevisoke gostote.
In the main study, Jevtana prolonged overall survival compared with the comparator medicine mitoxantrone.
V glavni študiji je zdravilo Jevtana v primerjavi s primerjalnim zdravilom mitotoksantronom podaljšalo skupno preživetje.
In the main study, switching to Atripla was as effective as remaining on the previous treatment combination.
V glavni študiji je bil prehod na zdravilo Atripla enako učinkovit kot nadaljnje jemanje prejšnje kombinacije zdravil.
In the main study, the patients who received Nivestim had severe neutropenia for a similar length of time as the patients who received Neupogen.
V glavni študiji so bolniki, ki so prejemali zdravilo Nivestim, hudo nevtropenijo imeli podobno dolgo kot bolniki, ki so prejemali zdravilo Neupogen.
In the maintenance phase, Nespo may continue to be administered as a single injection once weekly or once every two weeks.
Med obdobjem vzdrževanja je mogoče Nespa še naprej uporabljati v eni injekciji na teden ali na dva tedna.
In the major trials in ABSSSI the types of infections treated were confined to cellulitis/erysipelas, abscesses and wound infections only.
V večjih preskušanjih pri akutnih bakterijskih infekcijah kože in kožnih struktur (ABSSSI) so bile vrste zdravljenih infekcij omejene samo na celulitis/šen, abscese in okužbe ran.
In the majority of cases a single dose of Ruconest is sufficient to treat an acute angioedema attack.
V večini primerov za zdravljenje akutnega napada angioedema zadostuje en odmerek zdravila Ruconest.
In the majority of patients such treatment will be part of symptomatic palliation of the disease.
Pri večini bolnikov je tako zdravljenje del ublažitve simptomov bolezni.
In the majority of patients the pain was related to the patients’ underlying cancer or metastases or pre-existing or concomitant conditions.
Pri večini bolnikov je bila bolečina povezana z rakom ali zasevki pri bolniku in že obstoječimi ali sočasnimi boleznimi.
In the majority of patients who experienced gastrointestinal events, it was mild or moderate in severity.
Pri večini bolnikov, pri katerih so se prebavni dogodki pojavljali, so bili blagi ali zmerni.